BioNexus Gene Lab Corp.

NASDAQ: BGLC · Real-Time Price · USD
5.28
-0.08 (-1.49%)
At close: Aug 15, 2025, 12:13 PM

BioNexus Gene Lab Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
4.38M 5.93M 2.12M 2.12M
Short-Term Investments
n/a 3.31M 1.51M 1.55M
Long-Term Investments
1.27M 1.7M 1.15M 749.03K
Other Long-Term Assets
n/a n/a -2.72M n/a
Receivables
1.58M 857.26K 2.9M 3.36M
Inventory
1.39M 1.14M 977.81K 1.52M
Other Current Assets
2.88M 122.43K n/a 147.12K
Total Current Assets
7.43M 8.05M 6.02M 7.15M
Property-Plant & Equipment
1.74M 1.65M 1.57M 1.68M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
3M 3.35M 2.72M 2.42M
Total Assets
10.43M 11.4M 8.74M 9.57M
Account Payables
1.5M 1.4M 1.86M 2.01M
Deferred Revenue
95.88K n/a 23.12K 107.58K
Short-Term Debt
50.82K 13.2K 16.57K 39.51K
Other Current Liabilities
301.28K 180.91K 86.8K 71.81K
Total Current Liabilities
1.95M 1.63M 2M 2.33M
Long-Term Debt
n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a n/a
Total Long-Term Liabilities
159.74K 111.02K 71.07K 65.86K
Total Liabilities
2.11M 1.74M 2.08M 2.39M
Total Debt
210.56K 133.4K 56.77K 76.95K
Common Stock
17.33M 17.19M 10.93M 10.78M
Retained Earnings
-3.44M -1.84M 1.16M 1.51M
Comprehensive Income
-555K -677.29K -409.06K -100.26K
Shareholders Equity
8.32M 9.66M 6.67M 7.18M
Total Investments
1.27M 1.7M 1.15M 749.03K